Previous 10 | Next 10 |
2024-01-10 10:30:02 ET RBC Capital analyst issues UNDERPERFORM recommendation for SRPT on January 10, 2024 11:00AM ET. The previous analyst recommendation was Underperform. SRPT was trading at $117.6 at issue of the analyst recommendation. The overall analyst consensus :...
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 0.79% on the day to $107.67. Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery an...
2024-01-09 10:45:10 ET More on Sarepta Therapeutics Sarepta Therapeutics: Strong Q3 Earnings Help Offset Overblown Clinical Data Concerns Sarepta Therapeutics, Inc. (SRPT) Q3 2023 Earnings Call Transcript Sarepta Therapeutics, Inc. 2023 Q3 - Results - Earnings Call P...
2024-01-09 08:35:20 ET BT Brands ( BTBD ) +135% . Sentage Holdings ( SNTG ) +95% . Juniper Networks ( JNPR ) +23% jumps 25% on report HPE is nearing buyout deal. Syra Health ( SYRA ) +17% . Elicio Therapeutics ( ELT...
2024-01-09 07:15:00 ET Growth stocks were back in style in 2023 after a disappointing year in 2022. However, not every growth-oriented company kept pace with the broader indexes. Here are two that didn't: Sarepta Therapeutics (NASDAQ: SRPT) and DexCom (NASDAQ: DXCM) . These ...
2024-01-08 13:15:23 ET More on Sarepta Therapeutics Sarepta Therapeutics: Strong Q3 Earnings Help Offset Overblown Clinical Data Concerns Sarepta Therapeutics Q3 2023 Earnings Call Transcript Sarepta Therapeutics 2023 Q3 - Results - Earnings Call Presentation ...
– Preliminary total net product revenue is expected to total $1.145 billion for full-year 2023 – Preliminary ELEVIDYS net product revenue is expected to be $131.3 million for the fourth quarter and $200.4 million for full-year 2023, significantly exceeding consensus ...
2024-01-07 12:00:45 ET More on AbbVie, Bristol-Myers, etc. AbbVie: Still Expensive Despite The Great M&A Acumen Bristol-Myers Squibb Company (BMY) Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript) Merck & Co., Inc. (MRK) Goldman Sachs Health...
2024-01-04 07:30:00 ET Summary Dyne Therapeutics' early trial results for DM1 and DMD treatments show dose-dependent improvements, but data is preliminary. Despite promising DYNE-101 and DYNE-251 outcomes, limited participant numbers and short trial durations constrain robust asse...
2024-01-03 07:15:08 ET More on Dyne Therapeutics Seeking Alpha’s Quant Rating on Dyne Therapeutics Historical earnings data for Dyne Therapeutics Financial information for Dyne Therapeutics For further details see: Dyne surges on positive Phase 1/2...
News, Short Squeeze, Breakout and More Instantly...
Sarepta Therapeutics Inc. Company Name:
SRPT Stock Symbol:
NASDAQ Market:
Sarepta Therapeutics Inc. Website:
2024-06-26 10:06:00 ET When one player stumbles in a high-stakes competition, it's often to the glee of the other contenders. In mid-June, Pfizer 's (NYSE: PFE) gene-therapy candidate to treat Duchenne muscular dystrophy (DMD) didn't hit the mark in a late-stage clinical trial; it'd...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 3.2% to $126.57 on volume of 604,432,871 shares American Rebel Holdings Inc. (AREB) rose 152.5% to $0.76 on volume of 367,740,589 shares Sirius XM Holdings Inc. (SIRI) rose 1.0% to $2.93 on volume of 329...
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) is one of today's top gainers. The company's shares have moved 34.64% on the day to $166.22. Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies...